MP79-17 ADDITION OF CARBOPLATIN TO CHEMOTHERAPY REGIMENS FOR METASTATIC CASTRATE RESISTANT PROSTATE CANCER IN POST-2ND GENERATION HORMONE THERAPY SETTING: DOES IT IMPROVE SURVIVAL?

Mohamed E. Ahmed,Jack R. Andrews,Giovanni Motterle,Vidhu Joshi,R. Jeffrey Karnes,Eugene Kwon,Alan H. Bryce

MP79-17 ADDITION OF CARBOPLATIN TO CHEMOTHERAPY REGIMENS FOR METASTATIC CASTRATE RESISTANT PROSTATE CANCER IN POST-2ND GENERATION HORMONE THERAPY SETTING: DOES IT IMPROVE SURVIVAL?

2020

Mohamed E. Ahmed
Jack R. Andrews
Giovanni Motterle
Vidhu Joshi
R. Jeffrey Karnes
Eugene Kwon
Alan H. Bryce

INTRODUCTION AND OBJECTIVE:The clinical course in metastatic castrate resistant prostate cancer (mCRPC) can be complicated when patients have disease progression after prior treatment with 2nd gene...

Keywords:

Urology
prior treatment
Castrate-resistant prostate cancer
clinical course
Medicine
Hormone therapy
Chemotherapy
Carboplatin
disease progression

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations